Carter, John

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research

PARP inhibition in cancer therapyCancer therapeutics and mechanisms

Cited by 259

The Neuroplasticity-Associated Arc Gene Is a Direct Transcriptional Target of Early Growth Response (Egr) Transcription Factors

Li, L., Carter, J., Gao, X., Whitehead, J., & Tourtellotte, W. G. (2005) · Molecular and Cellular Biology

Neuroscience and Neuropharmacology ResearchMemory and Neural Mechanisms

Cited by 235

Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts

Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., et al. (2004) · Cancer Research

Cancer, Hypoxia, and MetabolismCancer therapeutics and mechanisms

Cited by 187

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 171